Prostate Cancer

Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.

Enzalutamide is a second-generation androgen receptor (AR) inhibitor which has improved overall survival (OS) in metastatic castration resistant prostate cancer (CRPC). However, nearly all patients develop resistance.

A first step towards a global nomogram to predict disease progression for men on active surveillance.

Signs of disease progression (28%) and conversion to active treatment without evidence of disease progression (13%) are the main reasons for discontinuation of active surveillance (AS) in men with localised prostate cancer (PCa).

Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial.

Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemical recurrence post prostatectomy to detect local recurrence and metastatic disease at low PSA levels. The aim of this study was to assess patterns of disease detection, predictive factors and safety using [18F]DCFPyL PET/CT versus diagnostic CT in patients being considered for salvage radiotherapy with biochemical recurrence post prostatectomy.

Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.

The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses.

Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries.

To test for baseline prostate cancer characteristics and survival differences after salvage radical prostatectomy (SRP) across 18 Surveillance, Epidemiology and End Results (SEER) registries from 2004 to 2016.

Stereotactic Body Radiotherapy and High-Dose Rate Brachytherapy Boost in Combination with Intensity Modulated Radiotherapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis - Beyond the Abstract

By definition, men with high to very high-risk prostate cancer are at substantially greater risk of local recurrence as well as developing metastasis and experiencing prostate cancer related mortality than men with intermediate or low risk disease.1,2 In addition, it is increasingly understood that men with unfavorable intermediate risk disease may experience outcomes more similar to that of men with high risk disease.3 Among the treatment options for men with high risk and unfavorable intermediate risk prostate cancer, prior randomized trials have suggested that the combination of external beam radiotherapy with a brachytherapy boost using either permanent seed implants (“low-dose rate” [LDR]) or temporary radioactive implants (“high-dose rate” [HDR]) leads to superior biochemical control compared to dose-escalated conventional fractionated radiation.4–6 As an alternative to a brachytherapy procedure, stereotactic body radiotherapy (SBRT), which is able to deliver HDR-like doses of radiation with high accuracy, has been used at our institution since 2006 in combination with pelvic nodal radiation to provide a similar level of “boosted” radiation to the prostate.  These men with unfavorable intermediate risk to very high-risk disease were either unable, unwilling, or not suitable to undergo a brachytherapy procedure. In the present study, we sought to describe our intermediate-term experience with SBRT boost and to compare it using propensity matching to men treated at the same institution with HDR boost.

Prostate Imaging and Data Reporting System Version 2 as a Radiology Performance Metric: An Analysis of 18 Abdominal Radiologists.

To determine expected trained provider performance dispersion in Prostate Imaging and Data Reporting System version 2 (PI-RADS v2) positive predictive values (PPVs).

This single-center quality assurance retrospective cohort study evaluated 5,556 consecutive prostate MRIs performed on 4,593 patients.

Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors-results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS).

Aside from urological and sexual problems, long-term (≥5 years after initial diagnosis) prostate cancer (PC) survivors might suffer from pain, fatigue, and depression. These concurrent symptoms can form a cluster.

Long Term Outcomes of Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with A Simultaneous Hypofractionated Boost to the Prostate For Very High Risk Adenocarcinoma of the Prostate, a Prospective Phase II Clinical Trial.

There remains limited data as to the feasibility, safety and efficacy of higher doses of elective radiation therapy (RT) to the pelvic lymph nodes in men with high risk prostate cancer. We conducted a phase II study to evaluate moderate dose escalation to the pelvic lymph nodes using a simultaneous integrated boost (SIB) to the prostate.

Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.

Background Although prostate MRI is routinely used for the detection and staging of localized prostate cancer, imaging-based assessment and targeted molecular sampling for risk stratification are an active area of research.